I was astonished at how much cash they will be burning this year.
Probably not unreasonable given the following plans just for their drug OCA:
* NDA/MAA filing for PBC in 1H 2015 * Initiate P3, etc. for NASH in 1H 2015 * Start P2 for Biliary Atresia in 2H 2015, and * Start P1 for Fibrosis by YE 2015
-JPM Slide No. 25.
On the bright side of the $3.3B valuation, raising another $200M or so won't cause much dilution of existing SHs.
So, now that ICPT is back on my radar, I'm mulling buying back in.... :-|
"The curious task of economics is to demonstrate to men how little they really know about what they imagine they can design." -F.A. von Hayek
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.